Is LSTA or NKGN more profitable?

NKGen Biotech's return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% NKGen Biotech N/A N/A -479.36%

Do analysts prefer ALGS or NKGN?

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 648.88%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer NKGN or SNTI?

Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 939.50%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is NKGN or SNTI more profitable?

NKGen Biotech's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Senti Biosciences N/A -532.05% -103.35%

Do analysts prefer NKGN or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, NKGN or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.51 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is NKGN or NNVC more profitable?

NKGen Biotech's return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% NanoViricides N/A -87.90% -78.69%

Do analysts recommend NKGN or EVAX?

Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 200.55%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is NKGN or EVAX more profitable?

NKGen Biotech's return on equity of 0.00% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Evaxion A/S N/A -73.56% -37.45%

NKGen Biotech (NKGN) Competitors

$0.15 +0.09 (+150.00%)

As of 02:46 PM Eastern

Compare

NKGN vs. LSTA, ALGS, SNTI, NNVC, and EVAX

Should you buy NKGen Biotech stock or one of its competitors? MarketBeat compares NKGen Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NKGen Biotech include Lisata Therapeutics (LSTA), Aligos Therapeutics (ALGS), Senti Biosciences (SNTI), NanoViricides (NNVC), and Evaxion A/S (EVAX). These companies are all part of the "pharmaceutical products" industry.

How does NKGen Biotech compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Lisata Therapeutics had 6 more articles in the media than NKGen Biotech. MarketBeat recorded 6 mentions for Lisata Therapeutics and 0 mentions for NKGen Biotech. Lisata Therapeutics' average media sentiment score of 0.81 beat NKGen Biotech's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Positive
NKGen Biotech	Neutral

Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 333.03%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lisata Therapeutics is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NKGen Biotech's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
NKGen Biotech	N/A	N/A	-479.36%

Lisata Therapeutics has higher revenue and earnings than NKGen Biotech. Lisata Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	185.55	-$16.59M	-$1.86	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

Summary

Lisata Therapeutics beats NKGen Biotech on 8 of the 13 factors compared between the two stocks.

How does NKGen Biotech compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

NKGen Biotech has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. NKGen Biotech's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
NKGen Biotech	N/A	N/A	-479.36%

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 648.88%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aligos Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Aligos Therapeutics has higher revenue and earnings than NKGen Biotech. Aligos Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.53	-$24.19M	-$8.69	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

In the previous week, Aligos Therapeutics had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Aligos Therapeutics and 0 mentions for NKGen Biotech. Aligos Therapeutics' average media sentiment score of 0.76 beat NKGen Biotech's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
NKGen Biotech	Neutral

Summary

Aligos Therapeutics beats NKGen Biotech on 10 of the 16 factors compared between the two stocks.

How does NKGen Biotech compare to Senti Biosciences?

NKGen Biotech (NYSE:NKGN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Senti Biosciences has higher revenue and earnings than NKGen Biotech. Senti Biosciences is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
Senti Biosciences	$38K	788.46	-$61.44M	-$1.92	N/A

Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 939.50%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

NKGen Biotech's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Senti Biosciences	N/A	-532.05%	-103.35%

NKGen Biotech has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Senti Biosciences had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Senti Biosciences and 0 mentions for NKGen Biotech. Senti Biosciences' average media sentiment score of 0.93 beat NKGen Biotech's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
Senti Biosciences	Positive

Summary

Senti Biosciences beats NKGen Biotech on 10 of the 15 factors compared between the two stocks.

How does NKGen Biotech compare to NanoViricides?

NKGen Biotech (NYSE:NKGN) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NanoViricides is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, NanoViricides' average media sentiment score of 0.23 beat NKGen Biotech's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
NanoViricides	Neutral

NKGen Biotech has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

NKGen Biotech's return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NanoViricides	N/A	-87.90%	-78.69%

Summary

NanoViricides beats NKGen Biotech on 7 of the 11 factors compared between the two stocks.

How does NKGen Biotech compare to Evaxion A/S?

NKGen Biotech (NYSE:NKGN) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

NKGen Biotech has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

In the previous week, Evaxion A/S had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Evaxion A/S and 0 mentions for NKGen Biotech. Evaxion A/S's average media sentiment score of 0.63 beat NKGen Biotech's score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
NKGen Biotech	Neutral
Evaxion A/S	Positive

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 200.55%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

NKGen Biotech's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has higher revenue and earnings than NKGen Biotech. Evaxion A/S is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
Evaxion A/S	$7.53M	4.05	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats NKGen Biotech on 10 of the 14 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKGN vs. The Competition

Export

Metric	NKGen Biotech	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$19.59M	$349.04M	$6.48B	$23.42B
Dividend Yield	N/A	N/A	2.67%	4.06%
P/E Ratio	-0.03	N/A	23.95	31.66
Price / Sales	N/A	171.60	536.37	101.28
Price / Cash	N/A	22.44	27.48	18.65
Price / Book	-0.06	4.76	10.44	4.71
Net Income	-$82.94M	-$141.03M	$3.56B	$1.08B
7 Day Performance	N/A	0.76%	0.83%	2.18%
1 Month Performance	N/A	-4.60%	1.78%	3.54%
1 Year Performance	-54.55%	56.78%	25.59%	24.66%

NKGen Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKGN NKGen Biotech	N/A	$0.15 +150.0%	N/A	-81.8%	$19.59M	N/A	N/A	N/A
LSTA Lisata Therapeutics	2.2901 of 5 stars	$3.35 -0.6%	$15.00 +347.8%	+42.3%	$30.52M	$170K	N/A	30
ALGS Aligos Therapeutics	3.3632 of 5 stars	$4.91 -8.1%	$38.50 +684.1%	-31.5%	$30.38M	$4.71M	N/A	90	News Coverage
SNTI Senti Biosciences	3.4647 of 5 stars	$0.97 -3.5%	$8.75 +806.4%	-63.1%	$30.07M	$20K	N/A	4
NNVC NanoViricides	0.3796 of 5 stars	$1.38 -8.0%	N/A	-19.2%	$29.87M	N/A	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NKGen Biotech (NKGN) Competitors

NKGN vs. LSTA, ALGS, SNTI, NNVC, and EVAX

How does NKGen Biotech compare to Lisata Therapeutics?

Summary

How does NKGen Biotech compare to Aligos Therapeutics?

Summary

How does NKGen Biotech compare to Senti Biosciences?

Summary

How does NKGen Biotech compare to NanoViricides?

Summary

How does NKGen Biotech compare to Evaxion A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NKGen Biotech (NKGN) Competitors

NKGN vs. LSTA, ALGS, SNTI, NNVC, and EVAX

How does NKGen Biotech compare to Lisata Therapeutics?

Do institutionals and insiders believe in LSTA or NKGN?

Does the media prefer LSTA or NKGN?

Which has more volatility & risk, LSTA or NKGN?

Do analysts recommend LSTA or NKGN?

Is LSTA or NKGN more profitable?

Which has stronger valuation and earnings, LSTA or NKGN?

Summary

How does NKGen Biotech compare to Aligos Therapeutics?

Is ALGS or NKGN more profitable?

Do analysts prefer ALGS or NKGN?

Do insiders and institutionals believe in ALGS or NKGN?

Which has more risk & volatility, ALGS or NKGN?

Which has preferable valuation and earnings, ALGS or NKGN?

Does the media prefer ALGS or NKGN?

Summary

How does NKGen Biotech compare to Senti Biosciences?

Which has stronger earnings & valuation, NKGN or SNTI?

Do analysts prefer NKGN or SNTI?

Is NKGN or SNTI more profitable?

Which has more volatility & risk, NKGN or SNTI?

Do institutionals & insiders believe in NKGN or SNTI?

Does the media favor NKGN or SNTI?

Summary

How does NKGen Biotech compare to NanoViricides?

Do analysts prefer NKGN or NNVC?

Do insiders & institutionals have more ownership in NKGN or NNVC?

Which has higher earnings and valuation, NKGN or NNVC?

Does the media favor NKGN or NNVC?

Which has more volatility and risk, NKGN or NNVC?

Is NKGN or NNVC more profitable?

Summary

How does NKGen Biotech compare to Evaxion A/S?

Which has more volatility and risk, NKGN or EVAX?

Does the media favor NKGN or EVAX?

Do insiders and institutionals have more ownership in NKGN or EVAX?

Do analysts recommend NKGN or EVAX?

Is NKGN or EVAX more profitable?

Which has higher valuation & earnings, NKGN or EVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools